Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer

NCT00705822 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

54

Enrollment

INDUSTRY

Sponsor class

Stopped low recruitment rate

Conditions

Prostatic Neoplasms

Interventions

DRUG: Docetaxel + Estramustine + Hydrocortisone
DRUG: Docetaxel + Prednisone

Sponsor

Sanofi